2026 Update on Clinical Trials in β-Thalassemia

Area of Science:

• Hematology
• Gene Therapy
• Pharmacology

Background:

• The treatment of beta-thalassemia has historically relied on blood transfusions and iron chelation therapy.
• Recent advancements have introduced disease-modifying and potentially curative therapeutic strategies.

Purpose of the Study:

• To review the clinical development of novel treatments for beta-thalassemia.
• To summarize approved therapies, ongoing clinical trials, and discontinued approaches.

Main Methods:

• Review of clinical development of novel treatments.
• Analysis of disease-modifying strategies targeting erythropoiesis, iron regulation, and red blood cell metabolism.
• Evaluation of gene addition, gene editing, and base editing technologies.

Main Results:

• Luspatercept and mitapivat are approved for improving hemoglobin and reducing transfusion needs.
• Gene therapies (betibeglogene autotemcel, exagamglogene autotemcel) have shown high rates of transfusion independence.
• Several other promising approaches have not met clinical endpoints, indicating therapeutic complexity.

Conclusions:

• Novel therapies, including gene-based and disease-modifying agents, are transforming beta-thalassemia treatment.
• Future efforts should focus on patient selection, real-world data, response criteria, pediatric access, and cost/accessibility challenges.